Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | GALR1 | P47211 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15823144 | 0.98 | CHRNB4 (0.47) | CHRNB4CHRNA3ACMSDPSMB5HPGD | |
| SCHEMBL968176 | 0.94 | CHRNB4 (0.46) | CHRNB4CHRNA3ACMSDPSMB5HPGD | |
| SCHEMBL3971131 | 0.84 | CHRNB4 (0.46) | CHRNB4CHRNA3HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL1055485 | 0.81 | CHRNB4 (0.43) | CHRNB4CHRNA3HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL27770435 | 0.78 | CHRNB4 (0.56) | CHRNB4CHRNA3HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL1773230 | 0.78 | HTR2C (0.48) | ACMSDPSMB5HPGDALDH1A1TDP1 | |
| SCHEMBL13782200 | 0.78 | CHRNB4 (0.49) | CHRNB4CHRNA3ACMSDPSMB5SERPINE1 | |
| SCHEMBL11034153 | 0.78 | CHRNB4 (0.49) | CHRNB4CHRNA3ACMSDPSMB5SERPINE1 | |
| SCHEMBL19910204 | 0.78 | CHRNB4 (0.49) | CHRNB4CHRNA3ACMSDPSMB5SERPINE1 | |
| SCHEMBL417070 | 0.78 | ACMSD (0.51) | CHRNB4CHRNA3ACMSDALDH1A1SERPINE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-2451793-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20120323001-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323001-A1 | BACE INHIBITORS | BACE1, BACE2, APP | CHRNB4 870/4885CHRNA3 1696/4885ACMSD 4884/4885 |
| US-20110009395-A1 | BACE INHIBITORS | BACE1, BACE2, APP | CHRNB4 870/4885CHRNA3 1696/4885ACMSD 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.